Skip Navigation

Rare disease stocks fly on Alexion acquisition

Rare disease stocks fly on Alexion acquisition

Synageva agreed to be acquired by Alexion Pharmaceuticals for about $8.4 billion in cash and stock, reports CNBC's Meg Tirrell.

01:27

Wed, May 6 201510:07 AM EDT

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'